Diagnostic and therapeutic ERβ, HER2, BRCA biomakers in the histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification
- PMID: 33465722
- DOI: 10.1016/j.anndiagpath.2020.151700
Diagnostic and therapeutic ERβ, HER2, BRCA biomakers in the histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification
Abstract
Several studies revealed that non-small cell lung cancers (NSCLCs) frequently express ER, PR, HER2 and carry BRCA mutation. However, these markers in histological subtypes of lung adenocarcinoma have not been thoroughly investigated. We retrospectively evaluated a total of 640 lung adenocarcinoma samples for ERα, ERβ, PR and HER2 expression by immunohistochemistry and western-blotting, for EGFR and BRCA mutation by real-time PCR and sequencing. Furthermore, HER2 amplification and mutation were explored in samples harboring immunopositivity HER2 using fluorescence in situ hybridization and real-time PCR, respectively. The micropapillary and invasive mucinous predominant adenocarcinoma were frequently detected the higher level of cytoplasmic ERβ (64.9% and 56.6%), HER2 (68.1% and 60.1%) protein expression. But, amplification of HER2 was detected in only three cases (3/110, 2.7%) and 26 HER2 mutations in 110 cases were identified (23.6%) in the HER2 immunopositivity patients. Logistic regression analysis showed that cytoplasmic ERβ (P = 0.032) and HER2 (P = 0.015) expression were independently associated with EGFR mutation. 8 patients (8/640, 1.25%) harbored pathogenic BRCA mutations, 6 with germline BRCA mutations and 2 with somatic BRCA1 mutations were detected with lacking ERβ, PR and HER2 expression. Acinar predominant adenocarcinoma had the higher percentage of BRCA mutations than other subtypes. A systematic examination of ERβ, HER2 and BRCA biomarkers could potentially be useful to diagnosis and identify patients with the histological subtypes of lung adenocarcinoma, who might benefit from the further individualized treatment of anti-hormone, anti-HER2 and/or PARP inhibitors therapeutics.
Keywords: Breast cancer susceptibility genes; Epidermal growth factor receptor; Estrogen receptor; Histological subtypes; Non-small cell lung cancer; Progesterone receptor.
Copyright © 2021 Elsevier Inc. All rights reserved.
Similar articles
-
Associations between epidermal growth factor receptor mutations and histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification in Chinese patients.Thorac Cancer. 2017 Nov;8(6):600-605. doi: 10.1111/1759-7714.12489. Epub 2017 Sep 20. Thorac Cancer. 2017. PMID: 28940943 Free PMC article.
-
HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.Lung Cancer. 2014 Sep;85(3):373-8. doi: 10.1016/j.lungcan.2014.06.007. Epub 2014 Jul 7. Lung Cancer. 2014. PMID: 25047676
-
Association of IASLC/ATS/ERS Histologic Subtypes of Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations in 320 Resected Cases.Clin Lung Cancer. 2015 May;16(3):209-15. doi: 10.1016/j.cllc.2014.10.004. Epub 2014 Oct 25. Clin Lung Cancer. 2015. PMID: 25467929
-
Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis.Eur J Surg Oncol. 2019 May;45(5):870-876. doi: 10.1016/j.ejso.2019.02.006. Epub 2019 Feb 16. Eur J Surg Oncol. 2019. PMID: 30833014
-
Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review.Curr Oncol. 2021 Aug 31;28(5):3384-3392. doi: 10.3390/curroncol28050292. Curr Oncol. 2021. PMID: 34590588 Free PMC article. Review.
Cited by
-
Impact of histopathological subtypes on invasive lung adenocarcinoma: from epidemiology to tumour microenvironment to therapeutic strategies.World J Surg Oncol. 2025 Feb 27;23(1):66. doi: 10.1186/s12957-025-03701-9. World J Surg Oncol. 2025. PMID: 40016762 Free PMC article. Review.
-
Selection of potential targets for stratifying congenital pulmonary airway malformation patients with molecular imaging: is MUC1 the one?Eur Respir Rev. 2023 Dec 20;32(170):230217. doi: 10.1183/16000617.0217-2023. Print 2023 Dec 31. Eur Respir Rev. 2023. PMID: 38123235 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous